ArticleDiabetes2013
The protective effects of CD39 overexpression in multiple low-dose streptozotocin-induced diabetes in mice.
Article in Diabetes, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 34 citations in OpenAlex.
- Role of adenosine A2a receptor in cancers and autoimmune diseases.Immunity, inflammation and disease · 2023Review
- Diabetes and hypertension: Pivotal involvement of purinergic signaling.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2021Review
- Adenosine Signaling in Autoimmune Disorders.Pharmaceuticals (Basel, Switzerland) · 2020Review
- STAT3 dictates β-cell apoptosis by modulating PTEN in streptozocin-induced hyperglycemia.Cell death and differentiation · 2020Article
- A3 receptor agonist, Cl-IBMECA, potentiate glucose-induced insulin secretion from MIN6 insulinoma cells possibly through transient CaResearch in pharmaceutical sciences · 2019Article
- Dysregulation of Adenosinergic Signaling in Systemic and Organ-Specific Autoimmunity.International journal of molecular sciences · 2019Review
- The Role of Extracellular Adenosine Generation in the Development of Autoimmune Diseases.Mediators of inflammation · 2018Review
- Increased Indoleamine 2,3-Dioxygenase and Quinolinic Acid Expression in Microglia and Müller Cells of Diabetic Human and Rodent Retina.Investigative ophthalmology & visual science · 2017Article
- The influence of gut-derived CD39 regulatory T cells in CNS demyelinating disease.Translational research : the journal of laboratory and clinical medicine · 2017Review
- CD39 overexpression does not attenuate renal fibrosis in the unilateral ureteric obstructive model of chronic kidney disease.Purinergic signalling · 2016Article
- Unlocking the Potential of Purinergic Signaling in Transplantation.American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons · 2016Review
- Role of the CD39/CD73 Purinergic Pathway in Modulating Arterial Thrombosis in Mice.Arteriosclerosis, thrombosis, and vascular biology · 2016Article
- Loss of survival factors and activation of inflammatory cascades in brain sympathetic centers in type 1 diabetic mice.American journal of physiology. Endocrinology and metabolism · 2015Article
- Adenosine signalling in diabetes mellitus--pathophysiology and therapeutic considerations.Nature reviews. Endocrinology · 2015Review
- Article
- The Role of Ectonucleotidases CD39 and CD73 and Adenosine Signaling in Solid Organ Transplantation.Frontiers in immunology · 2014Review
- CD39 and CD73 in immunity and inflammation.Trends in molecular medicine · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 5 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Islet allograft survival limits the long-term success of islet transplantation as a potential curative therapy for type 1 diabetes. A number of factors compromise islet survival, including recurrent diabetes. We investigated whether CD39, an ectonucleotidase that promotes the generation of extracellular adenosine, would mitigate diabetes in the T cell-mediated multiple low-dose streptozotocin (MLDS) model. Mice null for CD39 (CD39KO), wild-type mice (WT), and mice overexpressing CD39 (CD39TG) were subjected to MLDS. Adoptive transfer experiments were performed to delineate the efficacy of tissue-restricted overexpression of CD39. The role of adenosine signaling was examined using mutant mice and pharmacological inhibition. The susceptibility to MLDS-induced diabetes was influenced by the level of expression of CD39. CD39KO mice developed diabetes more rapidly and with higher frequency than WT mice. In contrast, CD39TG mice were protected. CD39 overexpression conferred protection through the activation of adenosine 2A receptor and adenosine 2B receptor. Adoptive transfer experiments indicated that tissue-restricted overexpression of CD39 conferred robust protection, suggesting that this may be a useful strategy to protect islet grafts from T cell-mediated injury.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.